IRWD
Ironwood Pharmaceuticals Inc. Class A Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$0.708
Максимум
$0.708
Минимум
$0.708
Объем
0.85M
Фундаментальные показатели компании
Статистические данные торговли
Связанные новости
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel syndrome with constipation (IBS-C); first completed Phase III
Связанные акции
HAE
Haemonetics Corporation
ADXN
Addex Therapeutics Ltd American Depositary Shares
PXDT
Pixie Dust Technologies Inc. American Depositary Shares
MEDS
TRxADE HEALTH Inc.
DRMAW
Dermata Therapeutics Inc. Warrant
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.